Compare Paramita Bangun Sarana Tbk. (PBSA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paramita Bangun Sarana Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Paramita Bangun Sarana Tbk. trades at Rp750 (market cap 2.28T, 994K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Paramita Bangun Sarana Tbk. is far larger — about 21.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PBSA | SCPI | |
|---|---|---|
Market Cap | 2.28T | 104.4B |
Volume | 994K | — |
Lot | 9.94K | — |
Turnover | 754.23M | — |
Average Price | 758.78 | — |
Value | 754.23M | — |
Indicative Equilibrium Price | 750 | — |
Indicative Equilibrium Volume | 56 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paramita Bangun Sarana Tbk.
PT. Paramita Bangun Sarana Tbk (the Company) was established based on the Notarial Deed No. 33 of Lenny Janis Ishak, S.H., dated November 27, 2002.
Read more on PBSA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
